Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions.
Cell Adhesion
Cytokines
/ metabolism
Humans
Immunity, Cellular
/ immunology
Ligands
Lymphocyte Activation
Phosphoproteins
/ metabolism
Phosphorylation
Programmed Cell Death 1 Receptor
/ metabolism
Proteome
/ analysis
Receptors, Antigen, T-Cell
/ metabolism
Signal Transduction
T-Lymphocytes
/ immunology
Transcriptional Activation
T cell
T cell receptor (TCR)
cell signaling
immunology
immunotherapy
inhibition mechanism
kinase-substrate relationships
mass spectrometry
phosphoproteomics
programmed cell death ligand 2 (PD-L2)
programmed cell death protein 1 (PD-1)
signaling networks
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
25 12 2020
25 12 2020
Historique:
received:
09
06
2020
revised:
10
09
2020
pubmed:
21
10
2020
medline:
26
3
2021
entrez:
20
10
2020
Statut:
ppublish
Résumé
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell-mediated anti-tumor responses. Consequently, therapeutic blockade of PD-1 enhances T cell-mediated anti-tumor immunity, but many patients do not respond and a significant proportion develop inflammatory toxicities. To improve anti-cancer therapy, it is critical to reveal the mechanisms by which PD-1 regulates T cell responses. We performed global quantitative phosphoproteomic interrogation of PD-1 signaling in T cells. By complementing our analysis with functional validation assays, we show that PD-1 targets tyrosine phosphosites that mediate proximal T cell receptor signaling, cytoskeletal organization, and immune synapse formation. PD-1 ligation also led to differential phosphorylation of serine and threonine sites within proteins regulating T cell activation, gene expression, and protein translation.
Identifiants
pubmed: 33077516
pii: S0021-9258(17)50680-8
doi: 10.1074/jbc.RA120.014745
pmc: PMC7939457
pii:
doi:
Substances chimiques
Cytokines
0
Ligands
0
PDCD1 protein, human
0
Phosphoproteins
0
Programmed Cell Death 1 Receptor
0
Proteome
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18036-18050Subventions
Organisme : NIAID NIH HHS
ID : R01 AI125640
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150597
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA231277
Pays : United States
Informations de copyright
© 2020 Tocheva et al.
Déclaration de conflit d'intérêts
Conflict of interest—A. M. received research support from NTB Pharma. The authors declare that they have no conflicts of interest with the contents of this article.
Références
J Biol Chem. 2020 Apr 3;295(14):4372-4380
pubmed: 31882544
Annu Rev Immunol. 2011;29:665-705
pubmed: 21219180
J Allergy Clin Immunol. 2015 Feb;135(2):564-7
pubmed: 25240786
Mol Cell Biol. 2013 Aug;33(16):3091-8
pubmed: 23732914
Mol Cell Proteomics. 2008 Sep;7(9):1598-608
pubmed: 18463090
Sci Signal. 2012 Jun 26;5(230):ra46
pubmed: 22740686
Nat Rev Immunol. 2004 Apr;4(4):301-8
pubmed: 15057788
Front Immunol. 2017 Dec 11;8:1653
pubmed: 29312284
Front Immunol. 2015 Jun 26;6:310
pubmed: 26167163
Proteomics. 2015 Jan;15(2-3):500-7
pubmed: 25307156
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Blood. 2009 Apr 2;113(14):3198-208
pubmed: 19190244
Nat Rev Immunol. 2004 Aug;4(8):603-16
pubmed: 15286727
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cell Rep. 2018 Apr 3;23(1):39-49
pubmed: 29617671
Mol Cell Biol. 2014 Apr;34(8):1474-85
pubmed: 24515435
Elife. 2017 Sep 26;6:
pubmed: 28949297
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Front Immunol. 2019 Mar 29;10:630
pubmed: 31001256
Immunity. 2006 Jun;24(6):741-52
pubmed: 16782030
Front Immunol. 2018 Nov 27;9:2737
pubmed: 30542345
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Cancer Res. 2018 Feb 1;78(3):706-717
pubmed: 29055015
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
PLoS One. 2009;4(5):e5430
pubmed: 19412549
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Cold Spring Harb Perspect Biol. 2010 Aug;2(8):a005512
pubmed: 20610546
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Nat Immunol. 2009 Nov;10(11):1185-92
pubmed: 19783989
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Commun. 2017 Dec 20;8(1):2214
pubmed: 29263426
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20296-301
pubmed: 18077330
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Blood. 2015 Jul 9;126(2):212-21
pubmed: 25979947
Biochem J. 2001 Jun 1;356(Pt 2):461-71
pubmed: 11368773
Curr Biol. 2018 Dec 3;28(23):3886-3891.e4
pubmed: 30471998
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
FEBS Lett. 2004 Sep 10;574(1-3):37-41
pubmed: 15358536